DGX
Quest Diagnostics Incorporated
NYSE: DGX · HEALTHCARE · DIAGNOSTICS & RESEARCH
$189.81
+2.13% today
Updated 2026-06-05
Market cap
$22.48B
P/E ratio
22.41
P/S ratio
1.99x
EPS (TTM)
$9.06
Dividend yield
1.60%
52W range
$162 – $213
Volume
0.9M
WallStSmart proprietary scores
58
out of 100
Grade: C+
Hold
Investment rating
6.0
Growth
B6.0
Quality
B6.0
Profitability
B5.0
Valuation
C+5/9
Piotroski F-Score
Moderate
2.4
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →199 stocks currently score above 75
Price targets
Analyst target
$208.62
+9.91%
12-Month target
$196.69
+3.62%
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy7 Buy9 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $164.00M — positive
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $9.88B | $9.25B | $9.87B | $11.04B | $11.28B | $11.9B |
| Net income | $946.00M | $854.00M | $871.00M | $992.00M | $252.00M | — |
| EPS | — | — | — | — | $9.06 | $10.74 |
| Free cash flow | $1.31B | $864.00M | $909.00M | $1.36B | $164.00M | — |
| Profit margin | 9.57% | 9.23% | 8.82% | 8.99% | 9.08% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-04 | KUPPUSAMY, KARTHIK | Sale | 4,827 | $121.81 |
| 2026-06-04 | KUPPUSAMY, KARTHIK | Sale | 3,320 | $127.73 |
| 2026-06-04 | KUPPUSAMY, KARTHIK | Sale | 8,147 | $200.00 |
Peer comparison
Smart narrative
Quest Diagnostics Incorporated trades at $189.81. representing a P/E of 22.41x trailing earnings. Our Smart Value Score of 58/100 indicates the stock is fair. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 2.37, it sits in the grey zone. TTM revenue stands at $11.28B. with profit margins at 9.08%.
Frequently asked questions
What is Quest Diagnostics Incorporated's stock price?
Quest Diagnostics Incorporated (DGX) trades at $189.81, on a P/E of 22.4x and a P/S of 2.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Quest Diagnostics Incorporated overvalued?
Quest Diagnostics Incorporated carries a Smart Value Score of 58/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of Quest Diagnostics Incorporated (DGX)?
The 12-month analyst consensus target is $208.62, about 9.9% above the current $189.81. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of DGX by 2030?
Our research-backed model puts the 2030 base case at $1,504.95, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is Quest Diagnostics Incorporated's revenue?
Quest Diagnostics Incorporated's trailing twelve-month revenue is $11.28B, and our model projects it reaching about $14.02B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Quest Diagnostics Incorporated's Altman Z-Score is 2.37, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDIAGNOSTICS & RESEARCH
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio1.99x
ROE13.90%
Beta0.59
50D MA$194.80
200D MA$189.20
Shares out0.11B
Float0.11B
Short ratio—
Avg volume0.9M
Performance
1 week+0.00%
1 month+2.60%
3 months+3.02%
YTD+15.42%
1 year—
3 years—
5 years—